Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia

Blood Adv. 2024 May 14;8(9):2133-2137. doi: 10.1182/bloodadvances.2023012111.

Authors

Kris Richardson^{1

2}, Jorge J Castillo^{1

2}, Shayna R Sarosiek^{1

2}, Andrew R Branagan^{2

3}, Catherine A Flynn¹, Kirsten Meid¹, Joshua N Gustine^{2

3}, Xia Liu^{1

2}, Amanda Kofides¹, Shirong Liu^{1

2}, Julie L Wolf⁴, Katherine A Kacena⁵, Christopher J Patterson¹, Maria Luisa Guerrera^{1

2}, Nicholas Tsakmaklis¹, Steven P Treon^{1

2}, Zachary R Hunter^{1

2}

Affiliations

¹ Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA.
² Department of Medicine, Harvard Medical School, Boston, MA.
³ MGH Cancer Center, Massachusetts General Hospital, Boston, MA.
⁴ Wolf Biostatistics, Boston, MA.
⁵ BioBridges, Boston, MA.

No abstract available

MeSH terms

Adenine* / analogs & derivatives
Adenine* / therapeutic use
Female
Humans
Male
Multiomics
Mutation*
Myeloid Differentiation Factor 88* / genetics
Piperidines* / therapeutic use
Prognosis
Pyrazoles / pharmacology
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Treatment Outcome
Waldenstrom Macroglobulinemia* / drug therapy
Waldenstrom Macroglobulinemia* / genetics